Japan Committee Recommends Lecanemab Approval
An advisory committee of Japan’s MHLW has given a favorable opinion for the approval of Eisai's Alzheimer's drug lecanemab, setting the stage for a possible full official approval in September, after which it would be co-commercialized with global partner Biogen.
You may also be interested in...
A new digital health venture set up by Eisai plans to start operations in Japan from April 2024 with services related to cognitive impairment and dementia, in line with the Japanese firm's therapeutic advances in this area.
Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.
Daiichi Sankyo, Chugai and Shionogi all marked double-digit revenue growth in the fiscal first quarter, while Astellas and Takeda saw some slow down. New products including Veozah and Leqembi buoyed performances, while the the expected upcoming US approval of a subcutaneous formulation may help restore Entyvio’s growth trajectory.